Viljoen A, et al. - Using the IQVIA CORE Diabetes Model (version 9.0), researchers evaluated the long-term cost-effectiveness of semaglutide 0.5 mg and 1 mg vs dulaglutide 1.5 mg (two once-weekly glucagon-like peptide-1 (GLP-1) receptor agonists) from a UK healthcare payer perspective, based on the head-to-head SUSTAIN 7 trial. According to the findings, once-weekly semaglutide is a cost-effective option for individuals with type 2 diabetes mellitus (T2DM) not achieving glycemic control on metformin in the UK vs treatment with dulaglutide. Semaglutide may both improve clinical outcomes and reduce costs.